Skip to main content
Equibles
IDXX logo

IDXX · Idexx Laboratories Inc /De

Track IDXX — free

Use IDXX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IDXX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$562.20 +8.88 (+1.60%) At close · Aug 19
Market Cap
$44.29B
Shares
78.78M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$562.20 Open$556.78 Day$555.00–575.56 52W close$526.44–766.68 Avg vol 30d635K Short int1.9M · 2.4% float · 4.0d Short vol31% Last earningsAug 4, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 4

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −9%
      below
      Price vs 50-day avg +0%
      above
      RSI (14) 49
      neutral
      MACD trend Negative
      52-week position 15%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +3%
      trailing
      6-month return −15%
      trailing
      YTD return −17%
      this year
      Relative strength −26%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $561 › 200d $616 — 200d above 50d
      Institutional flow Distributing
      -3% holders QoQ · +114 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      2.45% of float · ▼ -8.3% MoM · 4.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      1,278 holders — mid 3-yr range
      Squeeze score 53
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +10%
      Y/Y
      Gross margin 62%
      expanding
      EPS growth +23%
      Y/Y
      Free cash flow $1.1B
      Valuation P/E 39.5
      rich
      Balance sheet $269.8M
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 32%
      annualized · 1-yr
      Max drawdown −31%
      past year
      ATR 3.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 4
      Latest guidance · from the 8-K filed Aug 4, 2026
      Revenue · 2026 $4.7B – $4.75B
      prior FY $4.3B midpoint +9.7% Y/Y
      Organic growth · 2026 8.5% – 9.7%
      Reported growth · 2026 9.1% – 10.3%
      EPS · 2026 $14.69 – $14.94
      prior FY $13.08 midpoint +13.3% Y/Y
      CAG Diagnostics Recurring Revenue Growth Organic growth · 2026 9.5% – 10.7%
      Operating Margin · 2026 32.3% – 32.5%
      CAG Diagnostics Recurring Revenue Growth Reported growth · 2026 10.1% – 11.3%
      EPS Reported growth · 2026 12% – 14%
      Effective tax rate · 2026 21.1%
      Reduction in average shares outstanding · 2026 1.5% – 2%
      Share-based compensation tax rate benefit · 2026 1.3%
      Free Cash Flow (% of Net Income) · 2026 90% – 100%
      Prior guidance period ended · from the 8-K filed Nov 3, 2025
      Reported revenue growth · 2025 9.6% – 10.3%
      CAG Diagnostics Recurring Revenue Reported growth · 2025 8.3% – 9%
      CAG Diagnostics Recurring Revenue Organic growth · 2025 7.5% – 8.2%
      Organic revenue growth · 2025 8.8% – 9.5%
      Operating Margin · 2025 31.6% – 31.8%
      Share-based compensation tax rate benefit · 2025 1.7%
      EPS Reported growth · 2025 20% – 22%
      EPS Comparable growth · 2025 12% – 14%
      Reduction in average shares outstanding · 2025 2.5% – 3%
      Operating Cash Flow (% of Net Income) · 2025 105% – 115%
      Effective tax rate · 2025 20.8%
      Free Cash Flow (% of Net Income) · 2025 95% – 100%
      Guided vs delivered · last 4 settled
      Revenues full year 2024
      guided $3.93B – $4.04B
      $3.9B Miss −2.2%
      EPS full year 2024
      guided $10.84 – $11.33
      $10.67 Miss −3.7%
      Reported EPS full year 2023
      guided $9.74 – $9.90
      $10.06 Beat +2.4%
      Reported revenues full year 2023
      guided $3.64B – $3.65B
      $3.66B Beat +0.5%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 3 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −9% Bearish
      Price vs 50-day avg
      +0% Bullish
      RSI (14)
      49 Neutral
      MACD trend
      Negative Bearish
      52-week position
      15% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $561 › 200d $616 — 200d above 50d
      Institutional flow Distributing
      -3% holders QoQ · +114 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      2.45% of float · ▼ -8.3% MoM · 4.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      1,278 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $526 Now $562 · 15% Range high $767
      vs 200-day avg -9% vs 50-day avg +0%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Days sales outstanding 46.2 June 30, 2026 —
      Free cash flow non-GAAP $556.78M Six Months Ended June 30, 2026 —
      Inventory turns 1.4 June 30, 2026 —
      IDEXX inVue Dx placements 1,100 first quarter of 2026 —
      CAG Diagnostics capital instrument revenue growth 76% Q4 FY2025 —
      CAG Diagnostics capital instrument revenue organic growth 69% Q4 FY2025 —
      CAG Diagnostics recurring revenue growth 9% Full Year FY2025 —
      CAG Diagnostics recurring revenue organic growth 8% Full Year FY2025 —
      comparable gross margin gain non-GAAP 60 Q4 FY2025 —
      comparable gross profit growth non-GAAP 11% Full Year FY2025 —
      comparable operating expense growth non-GAAP 9% Full Year FY2025 —
      comparable operating margin expansion non-GAAP 90 Full Year FY2025 —
      new and competitive Catalyst placements 1,400 Q4 FY2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      IDXX
      Idexx Laboratories Inc /De
      this stock
      		$44.29B -16.9% +10.4% 39.5 2.4%
      TMO
      Thermo Fisher Scientific Inc.
      		 $217.80B +5.9% +14.5% 31.7 1.3%
      DHR
      Danaher Corp /De/
      		 $147.41B -7.6% +8.5% 37.2 1.7%
      NTRA
      Natera, Inc.
      		 $45.29B +41.9% -2.8% — 3.0%
      A
      Agilent Technologies, Inc.
      		 $41.92B +14.2% +6.4% 29.8 2.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      1,278
      % held
      93.5%
      Net QoQ
      +1.9M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,021
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      1.9M
      Days to cover
      4.0d
      Change
      -173.6K sh
      View
      Short Volume
      Short vol %
      31%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      14.2K
      Value
      $7.9M
      As of
      Jul 28, 2026
      View
      Off-Exchange
      Off-exchange %
      41.8%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      April McClain Delaney
      Amount
      $1.0K–$15.0K
      Traded
      Jan 13, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $4.3B
      Net income (FY)
      $1.1B
      EPS diluted
      $13.08
      View
      Buybacks
      Authorized
      shares 78.0M
      Remaining
      shares 3.7M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 4, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $1.1M
      Shares
      1.8K
      Filed
      Mar 3, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      IDXX -1.5% +3.2% -14.9% +0.6% -16.9%
      SPY -0.4% +2.9% +11.6% +3.0% +12.8%
      vs SPY -1.0% +0.3% -26.5% -2.4% -29.7%

      Capital returns

      Buyback program · as of Dec 31, 2025
      Authorized
      shares 78.00M
      Spent (derived)
      shares 74.30M
      Remaining
      shares 3.70M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 874716 CUSIP 45168D104 13F (30d) 1114 filings 1082 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)